Andrew McConaghie
Senior Writer
Andrew is a London-based journalist who has been writing about pharma, biotech and healthcare for over 20 years.
He writes on a range of topics, including biopharma R&D and commercial issues, digital healthcare and issues affecting patients and global healthcare systems, especially the UK’s NHS.
Latest From Andrew McConaghie
AZ’s ‘Long Shot’ COVID-19 Trial Of Diabetes Drug Farxiga Fails
The failure of the SGLT2 inhibitor is not unexpected, but allays any concerns that it could have worsened outcomes for patients with hypertension or heart disease.
Has UK Got Vaccine Strategy Right Again With Choice For Under 30s?
The UK has announced a ‘course correction’ on its vaccination program, and looks to have maintained public confidence so far – unfortunately the same cannot be said for EU countries
Regulators Reassure On AZ Vaccine Safety After Rare Side Effect Deemed Plausible
The EMA and MHRA issue parallel safety updates on the vaccine, with the UK offering an alternative of the Pfizer/BioNTech or Moderna vaccines to the under 30s.
Regulators Reassure On AZ Vaccine Safety After Rare Side Effect Deemed Plausible
The EMA and MHRA issue parallel safety updates on the vaccine, with the UK offering an alternative of the Pfizer/BioNTech or Moderna vaccines to the under 30s.
EMA Expected To Confirm AZ Vaccine Link To Rare Blood Clot
Growing evidence of an association between the vaccine and rare, sometimes fatal blood clots puts Europe’s vaccine program leaders in a difficult position.
NeuroRx Says COVID-19 Drug Improves Survival If Overstretched ICUs Excluded
Therapy shows some promise in helping COVID-19 respiratory failure patients but the US FDA may question company’s data cut.